Tissue Inhibitor of Matrix Metalloproteinase-2 in Nasopharyngeal Carcinoma

Amr Ahmed El Badry, MD; Amal Abou El-Fadle, MD; Abdel Latif El-Balshy, MD

Disclosures
In This Article

Results

The study comprised 20 controls and 30 cases of NPC that were staged clinically according to TNM classification. Eight cases were diagnosed as stage II, 12 cases as stage III, and 10 cases as stage IV; however, histopathologic examination of biopsies taken revealed the presence of 9 specimens classified as WHO type I, 6 specimens classified as WHO type 2, and 15 specimens classified as WHO type 3 ( Table 1 ).

Figure 1 shows the percent positivity of TIMP-2 protein in malignant cases. Figure 2 illustrates the comparison between the patients with malignancies and the controls.

The difference in percentage of TIMP-2 positivity between NPC patients and controls was statistically highly significant ( Table 2 ), as determined by Chi-square test (x2). There was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x2) ( Table 3 ).

Detection of TIMP-2 protein by Western blot in NPC patients (Lanes 2-8). TIMP-2 protein (21 KDa) was detected at the expected molecular weight (Lanes 2, 3, 5-8). Recombinant TIMP-2 protein positive control (Lane 1) and negative control for the immunodetection system (Lane 9) were included.

Detection of TIMP-2 protein by Western blot in NPC patients (Lane 2) and controls (Lanes 3-9). TIMP-2 protein (21 KDa) was detected at the expected molecular weight (Lanes 2, 5-7). Recombinant TIMP-2 protein (Lane 1) was included as a positive control.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....